Harlan Krumholz/LinkedIn
Dec 11, 2025, 12:50
Harlan Krumholz on Half-Life of Evidence and The Need for Real-Time Trials
Harlan Krumholz, Harold H. Hines Jr. Professor at Yale University, shared on LinkedIn:
”Clinical trials rarely come with expiration dates.
Yet the patients we treat today are not the same as those studied 40 years ago.
New trials on beta blockers after myocardial infarction highlight how much cardiology has changed, and how slowly our evidence adapts.
This is not simply about one therapy.
It is about the half-life of evidence and the need for modern, pragmatic, real-time trials that keep pace with evolving practice.
I explored this in my latest piece.”
Read the full article here.
Stay updated with Hemostasis Today.
-
Dec 12, 2025, 23:51Don’t Miss: IACH Post ASH 2025 Roundtable Debate
-
Dec 12, 2025, 23:37C-Reactive Protein and Cardiovascular Risk in the General Population: A European Heart Journal Study by Berkan Kurt et al.
-
Dec 12, 2025, 23:23Alta Schutte and Colleagues at National Hypertension Taskforce: Driving Single-Pill Therapy for Hypertension and More
-
Dec 12, 2025, 22:27Normal Counts, High Risk: Abdul Mannan Breaks Down JAK2 + Splanchnic Vein Thrombosis
-
Dec 12, 2025, 14:478 Posts Not to Miss From the ASH 2025 – Marc Carrier
-
Dec 12, 2025, 10:17Alyssa George on Clinical and Economic Impact of a Eptacog Beta
-
Dec 12, 2025, 09:53Ivan Budnik Awarded AHA Postdoctoral Fellowship! Aiming to Improve DVT Long-term Outcomes
-
Dec 12, 2025, 09:34Giles Platford on Baby Big: Plasma-Derived Drug Against Infant Botulism
-
Dec 12, 2025, 09:31Aravind Palraj: A Quick Guide to What Clinicians Actually Need